Sentence examples for biopharmaceuticals from inspiring English sources

Such outlays deter cash-strapped drug makers, especially those requiring only small quantities of a protein to complete a series of clinical trials and win regulatory approval.If manufacturing biopharmaceuticals in animals could be made more efficient, it would overcome the logjam that has been holding a flood of new therapeutic compounds back.

AbbVie had insisted that its main interest in Shire was its pipeline of new biopharmaceuticals, and not the benefits from Britain's lower corporate-tax rate.

The results are due in January next year.Nabi Biopharmaceuticals, based in Rockville, Maryland, is further ahead with its trials.

It's also home to the Technological Park of Andalucía, housing more than 500 businesses across sectors such as arts, agriculture, transportation, communication technology and biopharmaceuticals.

The successful implementation of the new tax regime will also see the construction of a new "green chemistry" facility at the University of Nottingham, ensure that the UK is the location for GSK's next biopharmaceuticals manufacturing plant, and secure further investment in continuous tablet manufacturing technology at Ware in Hertfordshire.

Evening (Eve) Spiker is the daughter of the billionaire businesswoman Terra Spiker, of Spiker Biopharmaceuticals.

Kiran Mazumdar-Shaw, boss of Biocon, an Indian biopharmaceutical company, describes a similar progression: "In the early days, we were taken with a big pinch of salt in India.

The biopharmaceutical revolution has barely begun.Meanwhile, between them, private companies, government agencies and venture-capital firms around the world will pour $4 billion into nanotech innovations this year.

Jeffrey Kindler, who has led the world's biggest drug company since 2006, will be replaced by 32-year Pfizer veteran Ian Read, who is currently the head of biopharmaceutical operations.

The social media messages falsely stated the biopharmaceutical company had tainted drug trial results and a US government agency had seized documentation as a result.

The auguries are also dim: 84 per cent of the participants at a recent biopharmaceutical conference in Monaco view funding as the industry's prime challenge.